Login to Your Account



Young blood's elixir: Alkahest draws $38M from Grifols to battle CNS disorder

By Michael Fitzhugh
Staff Writer

Friday, March 13, 2015
Betting on the restorative power of young blood to reverse cognitive decline in Alzheimer's disease and other central nervous system disorders, Grifols SA is taking a 45 percent stake in Stanford University spinout Alkahest Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription